Quarterly Updates13 Feb 2026, 09:02 pm
Sanjivani Paranteral Ltd Reports Strong Q3FY26 Performance with 20.25% YoY Revenue Growth
AI Summary
Sanjivani Paranteral Ltd, a Mumbai-based pharmaceutical company, has reported a robust performance for the quarter ended 31 December 2025. The company's revenue from operations grew by 20.25% YoY to Rs. 208.63 mn. The integration of SPL Infusion Pvt. Ltd., Pune, has strengthened the company's manufacturing footprint and contributed to the topline growth. The company's core business continues to show resilience and positive momentum across key markets. The Pune facility is expected to drive steady growth with improving capacity utilization.
Key Highlights
- Revenue from operations grew by 20.25% YoY to Rs. 208.63 mn
- Profit After Tax (PAT) stood at Rs. 26.16 mn, growing 37.8% YoY
- SPL Infusion Pvt. Ltd., Pune, has contributed to consolidated revenues for the first time
- The Pune facility is expected to drive steady growth with improving capacity utilization
- Core business demonstrates resilience and positive momentum across key markets